DCPrime obtains EMA Orphan Medicinal Product approval for AML vaccine

Date: 01/02/2012

Amsterdam, The Netherlands – DCPrime today announced that the Committee for Orphan Medical Products (COMP) of the European Medicines Agency has issued a positive opinion recommending DCPrime’s application for orphan drug designation of the company’s dendritic cell‐based cancer vaccine candidate, which targets Acute Myeloid Leukemia (AML). Please find the press release here.